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Bullet points clinical relevance/pullquote (12 words): 
Multiple prevention and health care strategies are needed to manage Keratinocyte Cancer. 
 
Abstract:  
Leiter et al. report on the increasing incidence of Keratinocyte Cancers (KC) in Germany. The true 
population burden is even larger then reported, as many of these new patients will develop multiple 
KC. KC puts a large burden on health care systems worldwide. Prevention and management 
strategies are needed to maintain high quality of care for all patients.   
More than Many 
In this issue of the JID, Leiter et al report on Non Melanoma Skin Cancer (NMSC) incidence and 
mortality trends and projections in two regions in Germany(Leiter et al., 2017). Histological subtype 
was not routinely gathered by the included cancer registries and therefore it was not possible to 
distinguish between basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) and other rare 
types of skin cancer. We prefer to use the term Keratinocyte Cancer (KC) to refer to BCC and SCC. The 
authors showed continuously increasing incidence rates since 1970 without evidence of any levelling 
off. Age-standardised incidence rates have increased 10 fold since 1970 and are expected to double 
up to by the year 2030, with rates above 200 patients per 100,000 person-years. The age-
standardized rates were standardized to the 1976 European standard population, but the proportion 
of elderly in the 1976 European standard population is much smaller than the true proportion of 
elderly in the German population. This  leads to a misinterpretation of the true KC burden, because 
elderly have the highest incidence rates of KC. Therefore, the authors presented crude rates, but for 
aforementioned reason the European standard population was updated in 2013 and includes a larger 
proportion of elderly. The authors report on the number of new patients, while the number of new 
tumors is much larger, because patients often develop multiple tumors over time.  It has been 
estimated that 50% of all patients with KC will develop at least one KC (Wehner et al., 2015). As in 
many other cancer registries worldwide, in Germany only the first KC is registered. Thus, these high 
incidence rates only represent part of the population burden of KC. Each subsequent KC will develop 
more rapidly after the previous one (Wehner et al., 2015). Although it is not feasible to register all KC 
due to limited resources of cancer registries, accurate information on KC incidence is imperative in 
order to inform stakeholders, such as health care policy makers, and to plan for future health care 
needs. Possibilities of estimating the total burden include the use of administrative health care claims 
data for KC surgeries, linkages to hospital records or pathology data or register all KC in a subsample 
of the total population (Chan et al., 2016).  
Burden of KC on the health care systems 
The diagnosis and treatment of KC imposes a high burden on healthcare systems, and collectively, 
they are among the most costly cancers (Housman et al., 2003). Furthermore, the increasing use of 
more costly treatments, such as Mohs surgery and photodynamic therapy is contributing to rising 
treatment costs.  Overuse of these treatments leads to unnecessary high costs. In the context of 
‘choosing wisely’ campaigns the AAD recommended not to treat uncomplicated small KC on the 
trunk and extremities with Mohs surgery and developed appropriate use criteria. In the Netherlands, 
reimbursement for PDT was  restricted since it was shown that inexpensive treatments such as 
topical 5-FU and imiquimod are non-inferior or even superior for superficial BCC (Arits et al., 2013). 
The choosing wisely campaign initiated the discussion on providing health care which is truly 
necessary, in order to maintain good access to health care in the future with an increasing KC 
burden, due to aging populations and increases in incidence rates. Evidence-based interventions on 
primary, secondary and tertiary prevention levels are needed (Figure 1).   
Primary Prevention: Ultraviolet (UV) behavior 
The authors note that despite skin cancer prevention campaigns behaviors in relation to UV exposure 
have not yet changed in Germany, nor has the introduction been reflected in decreased incidence 
rates. Since 1989, the German Society of Dermatology and the Association of Dermatological 
Prevention initiated primary prevention campaigns in Germany. In 2009, the SunPass-Healthy Skin  
was initiated in order to promote UV protection of children at daycare centres. Therefore, it is 
possible that it is too early to determine if the German prevention campaigns have been successful in 
reducing incidence of KC. Skin cancer has a long latency time, and the overall effect may not be 
apparent yet for this population. If there is an effect of public health campaigns, then this would be 
firstly observed among young people. The authors did not specifically examine the incidence rates by 
age. An analysis of KC treatment rates in Australia suggest that incidence rates among younger 
Australians are beginning to decline, possibly as result of public health campaigns that were 
implemented from the 1970s (Olsen et al., 2014). Results from the Nambour Skin Cancer Prevention 
Trial showed that regular use of sunscreen use is a cost-effective way of skin cancer control in 
Australia: During 5 years follow-up among 812 residents, 11 BCCs, 24 SCC and >800 AK were 
prevented (Gordon et al., 2009). It is estimated that sunscreen use is likely to be cost-effective over a 
long period of time. Two European trials among young students observed longer durations of 
sunbathing associated with sunscreen use (Autier et al., 2007). People who use sunscreen during 
intentional UV-exposure are able to spend longer periods of time in the sun without burning and 
thus for a subgroup of the population, sunscreen use may not result in reduced UV-exposure. 
However, most cumulative UV-exposure is probably gained through non-intentional exposure during 
outdoor activities, such as gardening, cycling or walking. Other trials among children and adults 
showed no increase of exposure time with sunscreen use (Autier et al., 2007; Bauer et al., 2005; 
Gallagher et al., 2000; Green et al., 1999). Therefore, public health campaigns should focus on 
reducing non-intentional exposure by  regular sunscreen use and other protection measures, such as 
avoiding being outdoors when UV levels are highest, seeking shade and wearing sun protective 
clothing and hats when outside. Although there is no evidence from RCTs that these other sun 
protection measures prevent KCs, they have been shown to reduce the prevalence of sunburn in the 
Australian population.   
Secondary Prevention: to screen or not to screen? 
The authors report that, contrary to incidence rates, mortality rates are decreasing. This decrease in 
mortality rates suggest that treatment and early detection has been crucial. In 2003 a pilot skin 
cancer screening program (i.e. the Skin Cancer Research to Provide Evidence for Effectiveness of 
Screening in Northern Germany (SCREEN)) was conducted. General Practitioners (GPs) and 
dermatologists were trained and performed screening in a 2-step manner: (1) the first whole body 
examination was performed by a GP, internal medicine physician or dermatologist and (2), if 
applicable, suspicious lesions were referred to a dermatologist. Possible positive results on 
melanoma mortality led to nationwide reimbursement of bi-annual skin cancer examinations by 
health insurance companies from 2008 onwards.   
It’s debatable, whether early detection of BCCs is cost-effective. Authors of a recent systematic 
review reported that size of BCC is one of the major determinants of associated health care costs and 
therefore they argued for early detection of BCC (Hoorens et al., 2016). However, BCC are slow-
growing tumors and large BCC are rare.  Therefore there is also a  risk of overdiagnosis (i.e. treating a 
BCC, which would not have progessed during a patient’ life). Treating a low-risk BCC among frail older 
people may cause more harm than benefits.  
The authors did not have data on immunosuppressive drug use or solid organ transplantations. Solid 
organ transplant recipients are up to 80 times more likely to develop a KC. Moreover, these tumors 
develop more rapidly and are more likely to be aggressive. In this high-risk group, screening for KC is 
beneficial.  
Tertiary prevention: Follow-up and chemoprevention of KC  
Reasons for follow up include: detection of metastasis, recurrences or new tumors. There is a subset 
of KC patients who never develop a second BCC or SCC during their lifetime (Wehner et al., 2015). 
Thus, follow-up may not be indicated for all patients. Yet, it is difficult to predict which patients will 
develop a subsequent KC in the future. A clinical prediction model to predict the absolute risk for a 
second KC could be used to guide decisions on tailored follow-up. Recently a prediction model to 
predict the absolute risk on a second BCC has been developed, but this model needs external 
validation (Verkouteren et al., 2015).  
According to the German guidelines, instruction for self-examination and an annual follow-up is 
recommended for 3 years for each patient with BCC and possibly life-long for high-risk tumors or 
patients. However, the benefit of early detection of BCC, because they are slow-growing and rarely 
metastasize, is the subject of considerable debate. Therefore, in other countries, such as Australia, 
no specific follow-up scheme is recommended for histologically cleared low-risk tumors. In the UK 
guidelines state that follow-up can also be performed by a specialized trained nurse or primary care 
physician.  
A strategy to prevent the development of new tumors is the use of chemoprevention. Among high 
risk groups, such as organ transplant recipients and patients with multiple KC it is more likely that the 
benefits outweigh the potential harms of medication use. A RCT of nicotinamide use among patients 
with at least 2 KC showed a decrease of 23% in incidence of subsequent KC after 1 year. Another 
candidate is a single course of 5-FU, which resulted in a decrease in surgery for SCC during 1 year 
follow-up among patients with at least 2 KC (Weinstock et al.). 
Role of the GP in the management of KC 
The authors also argue that GPs should play a larger role in the management of KC and that they 
should receive training for this task. The latter is of pivotal importance. This starts with sufficient 
training in the curriculum of undergraduates in medical school, which should be followed by 
substantial postgraduate training in the GP training program and sufficient opportunities to assess 
diagnostics and management skills in clinical practice. Currently, dermatology is not specifically 
required in the training program of GPs in Germany and other European countries. A high quality of 
care is a prerequisite for substitution of hospital care by the GP.  GPs must be provided sufficient 
education, time and resources in order to manage KC. 
In Australia the GP has a larger role in skin cancer compared to most European countries and the US. 
In the past two decades has seen the emergence of skin cancer clinics staffed by GPs, particularly in 
Queensland, the state with the highest incidence of KC and melanoma. General practitioners can 
specialize in “skin cancer medicine”, and receive extra training and accreditation. GPs play a pivotal 
role in the early detection, diagnosis and management of many skin cancers, especially in rural areas 
(Askew et al., 2007).  
In the UK, services for the management of low-risk BCCs can be commissioned from accredited GPs 
with specialist dermatology training who participate in regular histological accuracy audit (Cancer, 
2006). UK guidelines on KC also recommend self-examination or follow-up in primary care for 
primary adequately treated BCCs (Telfer et al., 2008). Patients with chronic immunosuppression, 
genetic conditions, or incompletely excised BCCs, will be followed up in secondary care. GPs have no 
primary management role in treating SCCs in the UK, with all suspected lesions referred urgently to 
secondary care. Currently there remains limited dermatology  training for GPs in the UK at both 
undergraduate and postgraduate levels (Schofield et al., 2009; Yaakub et al., 2016). 
Management of KC by GPs may decrease the workload for dermatologists, but also has advantages 
for patients. Patients may not need to attend hospital clinics but rather be treated by the physician 
they are familiar with. In addition, if quality of care in primary care is sufficiently high, costs for the 
health care system and possible out of the pocket costs for patients of the GP are generally lower 
compared to a medical specialist.  
Conclusion 
In order to manage KC in the future, prevention on different levels is needed. We argue that the 
majority of KCs in the general population are detected early enough and therefore secondary 
prevention strategies (i.e. screening) on a population level for KC may not be cost-effective. Long-
term experience and data from Australia suggests that it takes decades to measure the effect of 
primary prevention campaigns. Incidence rates among young people plateaued around the year 
2000, and have declined since that time, while primary prevention campaigns started in the 1970s. 
As overall incidence rates in Germany and many countries are still increasing, tertiary prevention 
strategies are needed to manage the current and future KC burden. Strategies include tailored 
follow-up and chemoprevention. Management of KC in primary care is a possibility, but sufficient 
education, time and resources are pivotal. Some strategies may be generalizable, while others are 
country-specific and depend on health care system factors. Yet, the KC epidemic is universal and calls 
for for empirical evidence of cost-effective  management strategies into the future. Cancer registries 
fulfill an important role to monitor current and future efforts being made.  
 
Figure 1: Three levels of prevention of keratinocyte cancer 
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